SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is seeing intense volatility as investors debate the impact of the ongoing conflict in Iran and subsequent energy market instability on the company's valuation. The community is sharply divided, with supporters defending the administration's strategic maneuvers while a significant portion of the retail base expresses frustration over the stock's downward trend and the broader macroeconomic uncertainty.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is facing intense selling pressure following a series of analyst downgrades that highlight long-standing concerns over smartphone demand, memory chip shortages, and the gradual loss of Apple as a modem customer. Despite active community debate over the company's valuation and its aggressive pivot toward AI, robotics, and automotive technology, the stock continues to struggle with downward momentum as investors weigh short-term margin headwinds against its long-term diversification strategy.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure as investors rotate out of the gaming sector following the unveiling of Google's AI-driven 3D world creation tool, Project Genie. While some community members view the sell-off as an overreaction and a potential buying opportunity, others are actively betting on further declines, citing concerns over regulatory headwinds, platform safety, and long-term valuation.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Investors are increasingly rotating into this ETF as a defensive hedge amid market volatility, with the community actively debating the long-term benefits of its dividend growth profile compared to pure growth alternatives. Sentiment remains focused on accumulating shares during pullbacks to leverage the fund's historical compounding power and stable yield potential.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently trending as investors debate the impact of reportedly delayed AI model rollouts, with community sentiment sharply divided between those viewing the pullback as a buying opportunity and others concerned about heavy AI infrastructure spending. Traders are closely monitoring the stock's consolidation around key technical support levels while tracking internal cost-saving initiatives and broader market sensitivity to AI-driven capital expenditure.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, Ketjen, and All Other. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The All Other segment refers only to the FCS business that did not fit into any of the company’s core businesses. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is trending as investors weigh its aggressive divestment strategy and improved balance sheet against persistent volatility in lithium prices. The community remains focused on the company's long-term pivot toward energy storage and EV demand, while balancing immediate concerns over upcoming earnings and broader geopolitical supply chain risks.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is attracting significant attention as investors anticipate the upcoming presentation of final overall survival data from the Phase III HARMONi-A trial. The community remains focused on the company's aggressive clinical pipeline, with strong bullish sentiment surrounding a potential short squeeze and high insider confidence ahead of multiple high-profile investor conferences.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is currently a primary focus among investors as market participants debate the impact of potential geopolitical shifts and energy sector consolidation on the company's valuation. While some traders are closely watching for a breakout from long-term technical patterns, the community remains divided over whether the stock is an undervalued growth play or a target for a larger energy sector acquisition.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is experiencing heightened volatility and intense community scrutiny as investors weigh the potential impact of a proposed 31.5% share issuance to acquire Distributed Technologies Research against long-standing concerns regarding share dilution and weak financial delivery. While some participants view the firm's pivot toward stablecoin infrastructure and institutional custody as a significant long-term catalyst, many remain skeptical, labeling the stock as a speculative momentum play susceptible to pump-and-dump cycles.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

PSLV is capturing significant market attention as investors increasingly favor its physical silver backing over paper-based ETFs amid concerns regarding COMEX vault depletions and structural supply shortages. The community is actively debating the impact of geopolitical instability and potential supply squeezes, with many members interpreting recent price volatility as a calculated attempt by financial institutions to shake out retail investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The agency’s assessment was based on the company’s Phase 2 data package.</li><li>The FDA supported the use of Clinical Dementia Rating Scale-Sum of Boxes, a scale used to determine dementia severity.</li><li>INmune will enroll about 300 participants over nine months to confirm efficacy before expanding to a 1,000-patient Phase 3 trial.</li></ul>INmune Bio, Inc (INMB) stock gave up some of its pre-market gains to trade 3% higher on Thursday morning, after the company said it has received official U.S. Food and Drug Administration (FDA) meeting minutes confirming regulatory alignment on its integrated Phase 2b/3 development plan for XPro1595, a potential therapy for early Alzheimer’s disease.The FDA supported INmune Bio’s precision medicine strategy, which uses a trial design to identify patients whose inflammatory biomarker profiles are tied to soluble tumor necrosis factor (TNF) signalling, the treatment’s biological target.The agency’s assessment was based on the company’s Phase 2 data package, which included cognitive and biomarker findings.“XPro1595 represents a differentiated approach to Alzheimer’s disease, based on precision patient selection and selective immune modulation, with a favorable safety profile that included zero cases of ARIA in our Phase 2 study,” said David Moss, INmune Bio’s CEO.<h2 class="st-heading-2">FDA Approval Details</h2>The FDA supported the use of the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) as the primary endpoint, a scale used to assess dementia severity and track progression. It also did not object to INmune Bio’s plan to enroll patients identified by key inflammation-related biomarkers linked to the drug’s target.The company said that the Phase 2b part will feature a nine-month evaluation period to build the clinical foundation for a subsequent Phase 3 study. INmune will enroll about 300 participants over nine months to confirm efficacy before expanding to a 1,000-patient Phase 3 trial lasting 18 months.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned’ bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/INMB_jpg_241e60ecf9.webp" alt="INMB.jpg">One user noted a tepid market reaction and said that it was an “excellent time to add” the stock to their portfolio.<stembedurl>https://stocktwits.com/10baggerPete/message/644778292</stembedurl>Another user said the company was “moving in the right direction.”<stembedurl>https://stocktwits.com/bioinvestorrr/message/644769951</stembedurl><a href="https://stocktwits.com/symbol/INMB">INMB shares</a> have declined around 0.6% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-retail-sales-slump-in-january/cZRTn3fR4rK">Tesla’s China Retail Sales Slump 45% In January: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial?

The FDA meeting minutes suggest INmune Bio’s late-stage Alzheimer’s trial design is on track.

Equity

INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised INmune Bio from a "sell" rating to a "hold" rating in a research note on Sunday...

Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB

Praetorian PR LLC lowered its stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 99.3% in the second quarter, according to the company in its most recent disclosure with the Securities and...

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Investing.com --  INmune Bio  (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its investment case.

INmune Bio Inc. (INMB) on Monday said that its experimental drug XPro did not show any effects in the intent-to-treat population in a mid-stage study evaluating its effectiveness in early Alzheimer’s Disease (AD) with biomarkers of inflammation.INmune’s stock fell about 59% in morning trade at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107380/0/en/INmune-Bio-Reports-Key-Findings-from-Phase-2-MINDFuL-Trial-of-XPro-in-Early-Alzheimer-s-Disease.html">trial </a>enrolled 208 participants with early-stage Alzheimer’s to asses the drug’s potential in slowing cognitive decline by tackling neuroinflammation.The primary endpoint of the study was a change in cognition over 6 months on the Early Mild Alzheimer’s Cognitive Composite (EMACC). EMACC is a tool used in clinical trials and research to assess cognitive changes in individuals with early or mild Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI).The primary endpoint was not met in the intent-to-treat population.However, changes in clinical measures of cognition, behavior, and an AD-related biomarker demonstrated a benefit in a subpopulation of 100 early Alzheimer's patients with inflammation biomarkers who were treated with XPro, compared to patients treated with placebo, the company said.CEO RJ Tesi said that the findings lay the foundation for advancing XPro as a “promising treatment option” for Alzheimer’s.XPro treatment was safe and well-tolerated, the company added.<a href="https://stocktwits.com/symbol/INMB">INmune</a> now intends to schedule an end-of-mid-stage meeting with the U.S. Food and Drug Administration (FDA) in the last quarter of 2025 to define the path forward for a pivotal trial to support XPro approval in early Alzheimer’s.Despite the drop in INMune stock during Monday’s trading session, retail sentiment around the stock is trending in the ‘extremely bullish’ territory on Stocktwits.INMB stock is down by about 53% this year and by about 74% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-flu-vaccine-show-positive-results-in-late-stage-trial/chmZitPRR72">Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial

The primary endpoint of the study was not met in the intent-to-treat population, the company said. 

INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results

Investing.com --  INmune Bio  Inc. (NASDAQ:INMB) stock fell 60% in pre-market trading Monday after the company reported mixed results from its Phase 2 MINDFuL trial of XPro in early Alzheimer’s disease patients.

INmune Bio Inc. (INMB) on Friday said that it entered into securities purchase agreements with two healthcare-focused institutional investors for the purchase and sale of 3 million shares of its common stock.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/27/3106725/0/en/INmune-Bio-Inc-Announces-Approximately-19-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html">said</a> that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share. The proceeds from the offering are expected to be about $19 million, excluding costs such as fees to the placement agency Alliance Global Partners.<a href="https://stocktwits.com/symbol/INMB">INmune Bio</a> said that it intends to use the proceeds from the offering for working capital purposes and general corporate purposes.The closing of the offering is expected to occur on or about June 20.INMB shares are down 19% on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around INmune Bio is unmoved within the ‘extremely bullish’ territory over the past 24 hours, while retail chatter stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_2_24_21_PM_png_cb3ab03d42.webp" alt="INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the company is headed to a year-long downtrend.<stembedurl>https://stocktwits.com/CharlesIV/message/619287462</stembedurl>Another user opined that a stock offering before data results is “sketchy.”<stembedurl>https://stocktwits.com/EddieGon/message/619286742</stembedurl>INmune Bio is slated to present topline results from its mid-stage Alzheimer’s trial, the MINDFuL study, on Monday. The trial is testing its lead drug candidate XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation.The MINDFuL study will compare XProTM to placebo to find out whether XPro affects memory, functioning, and behavior. The study will also evaluate whether XPro is safe and tolerable.INMB stock is up by 9% this year and down by about 41% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-stock-rises-on-us-supreme-court-ruling-in-favor-of-health-insurers-covering-preventive-care/chmWPN2RRe5">Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Stock Slumps On 3M Share Offering Ahead Of Mid-stage Trial Data, But Retail Remains Bullish 

The company said that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share.

INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday.The company will present findings from its MINDFuL study, a placebo-controlled trial testing its lead drug candidate XPro in patients showing early signs of Alzheimer’s.&nbsp;The study participants consisted of 208 patients diagnosed with mild cognitive impairment or mild Alzheimer's disease.&nbsp;The average age of the participants was 72 years. In all of the participants, biomarkers of inflammation were present.&nbsp;The inflammatory biomarkers observed were elevated C-reactive protein levels, along with increased ESR and higher HbA1c values and genetic markers such as the APOE ε4 allele.&nbsp;Participants were randomized 2-to-1 to receive weekly doses of XPro or a placebo for just under six months.The main goal of the study is to assess cognitive change using a custom measurement tool called the early and mild Alzheimer's cognitive composite&nbsp;(EMACC), designed to detect subtle shifts in early-stage Alzheimer’s.&nbsp;Previous data showed the EMACC aligns well with other standard assessments like MMSE and CDR-SB.The company reported that over two-thirds of participants carried the APOE ε4 gene, and nearly two-thirds qualified through more than one biomarker.&nbsp;Roughly 72% of patients screened for the trial were not enrolled, mostly due to more advanced disease.In addition to cognitive scoring, the study includes secondary measures such as evaluations of daily living, neuropsychiatric symptoms, and biological markers.XPro is part of the company’s broader immune-targeting drug platform, which focuses on conditions believed to stem from chronic inflammation.&nbsp;<a href="https://stocktwits.com/symbol/INMB">INmune</a> is also exploring XPro for use in depression, alongside other programs for cancer and rare skin disorders.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 344% surge in 24-hour message volume.One user said that the timing of the announcement indicated confidence from the company, noting that results slated for early Monday were unlikely to disappoint.<stembedurl>https://stocktwits.com/winefan/message/619189685</stembedurl>They also referenced commentary from&nbsp;“pharma bro”&nbsp;Martin&nbsp;Shkreli, who previously stated that if the drug proves effective, the stock could surge dramatically, possibly even reaching triple-digit levels.Another user noted the pre-market Monday scheduling as a potentially encouraging signal but said they wouldn’t celebrate until the actual data is released.<stembedurl>https://stocktwits.com/BoilerKing/message/619167991</stembedurl>The stock has risen 27.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week

INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders.

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

INMB
INmune Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INMB News

INMBINmune Bio Inc